Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

narmac

Jan 29, 2019 07:42PM

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

Nextblockbuster

Jan 30, 2019 07:36AM

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

tada

Jan 30, 2019 10:04AM

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

Nextblockbuster

Jan 30, 2019 10:14AM

KayakerBC

Rank: Treasurer [?]

Points: 1691 [?]

Votes: 23 Score: 2.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

in response to

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

Nextblockbuster

posted on Jan 30, 2019 12:14PM

If that's case i wonder why we have yet to hear any large deal with Zenith.....

It's a possibility. We just have to wait it out.

Zenith is currently in an ongoing Phase 2 with ZEN-3694. From the latest MD&A....

"On June 4, 2018,we announced that we had initiated the Phase 2 portion of the ongoing mCRPC clinical trial in patients that have progressed on an androgen receptor antagonist (“ARi").In Phase 2, weare focused on continuing the evaluation of efficacy and safety of ZEN-3694 in combination with enzalutamide (Xtandi)...."